Mesoblast (NASDAQ: MESO) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Mesoblast to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares Mesoblast and its competitors top-line revenue, earnings per share (EPS) and valuation.
Mesoblast’s competitors have higher revenue and earnings than Mesoblast. Mesoblast is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and target prices for Mesoblast and its competitors, as provided by MarketBeat.
||Strong Buy Ratings
Mesoblast presently has a consensus target price of $14.25, indicating a potential upside of 141.94%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.61%. Given Mesoblast’s stronger consensus rating and higher probable upside, research analysts clearly believe Mesoblast is more favorable than its competitors.
Institutional & Insider Ownership
2.9% of Mesoblast shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Mesoblast and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk and Volatility
Mesoblast has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500. Comparatively, Mesoblast’s competitors have a beta of 1.47, meaning that their average stock price is 47% more volatile than the S&P 500.
Mesoblast beats its competitors on 8 of the 13 factors compared.
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.